Abstract:OBJECTIVE:To explore the clinical patterns and clinical significance for RET screening in adrenal pheochromocytoma (PHEO) associated with multiple endocrine neoplasia type 2A (MEN2A).METHODS:The clinical data of 32 PHEO patients with MEN2A from 13 unrelated MEN2A pedigrees from August 1989 to January 2013 were analyzed. The comprehensive medical data included systemic examinations and germline RET gene screening.RESULTS:Among 68 patients belonging to 13 MEN2A families, 32 (47.1%) presented with PHEO. There were 19 males and 13 females with a mean age of (41 ± 12) years. And the mean maximum diameter of PHEO was (4.6 ± 2.2) cm. The diagnosis of PHEO was made after medullary thyroid carcinoma (n = 12, 37.5%), simultaneously (n = 12, 37.5%), initially (n = 7, 21.9%) and death during appendectomy for PHEO-induced hypertensive crisis (n = 1, 3.1%). The diagnosis of PHEO was made before (n = 22) or after (n = 10) clinical screening. The former had 12 symptomatic cases while the latter only 1 case (12/22 vs 1/10, P = 0.024).Except for 5 asymtomatic fatal cases during non-PHEO operations, bilateral PHEO was found in 17 cases including 3 unilaterally treated cases developing another PHEO in contralateral adrenal with a lag period of 5, 10 and 17 years. There were 7 symptomatic patients in bilateral cases versus 6 in unilateral cases (7/17 vs 6/10, P = 0.440). Twenty-five patients underwent PHEO surgery: laparascopic approach in 14 cases (8 with bilateral simultaneous adrenalectomy) and open approach in 11 (2 with bilateral simultaneous adrenalectomy). And 10 patients undergoing bilateral adrenal-sparing operations or adrenalectomy required hormonal replacement therapy. During a mean observation period of 72 (1-282) months, no local recurrence, distant metastasis or Addisonian crisis were noted in 25 cases (contralateral relapse in 3 cases). Among them, 2 cases developed adrenocortical insufficiency unresponsive to an adjustment of hormonal doses.RET screening showed 4 recurrent missense substitutions in 32 MEN2A-PHEO patients: p. C634Y exon 11 (n = 27, 84.4%), p. C634R exon 11 (n = 3, 9.4%), p. C634F exon 11 (n = 1, 3.1%) and p. C618R exon 10 (n = 1, 3.1%).CONCLUSIONS:The mutations of RET proto-oncognene of PHEO in MEN2A are frequently located at codon 634. A combination of pedigree examination and RET gene screening may facilitate an early diagnosis and early treatment of asymptomatic PHEO patients in MEN2A.Laparoscopic cortical-sparing adrenalectomy for preserving adrenocortical function is a preferred surgical approach.

RET c.1901G>A and Novel SLC12A3 Mutations in Familial Pheochromocytomas

RET S409Y Germline Mutation and Associated Medullary Thyroid Carcinoma.

C634Y mutation in RET -induced multiple endocrine neoplasia type 2A: A case report

Different RET gene mutation-induced multiple endocrine neoplasia type 2A in 3 Chinese families.

[The Clinical Patterns and RET Proto-Oncogene Identification of Pheochromocytoma in 13 Multiple Endocrine Neoplasia Type 2A Pedigrees].

The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees]

RET Germline Mutations Identified by Exome Sequencing in a Chinese Multiple Endocrine Neoplasia Type 2a/familial Medullary Thyroid Carcinoma Family.

Genetic Analysis of a Chinese Han Family with Multiple Endocrine Neoplasia Type 2A.

Detection of the Mutation of RET Proto-Oncogene in a Pedigree with Multiple Endocrine Neoplasia 2 A

Multiple Endocrine Neoplasia Type 2A Caused by a P.c618r RET Proto-Oncogene Mutation in a Chinese Pedigree

Screening of RET Gene Mutation in a Large Chinese Pedigree with Multiple Endocrine Neoplasia Type 2A

MEN2 phenotype in a family with germline heterozygous rare RET K666N variant

Detection of the RET proto-oncogene in a family with multiple endocrine neoplasia type 2A syndrome

Spectrum of Germline RET Variants Identified by Targeted Sequencing and Associated Multiple Endocrine Neoplasia Type 2 Susceptibility in China

p.L105Vfs mutation in a family with thymic neuroendocrine tumor combined with MEN1: a case report

Ret Proto-Oncogene Mutations Are Restricted To Codons 634 And 918 In Mainland Chinese Families With Men2a And Men2b

RET Proto-Oncogene Genetic Screening of Families with Multiple Endocrine Neoplasia Type 2 Optimizes Diagnostic and Clinical Management in China.

Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma

Multiple Endocrine Neoplasia 2A with RET Mutation P.cys611tyr: A Case Report.

RET 634 germline/gonadal mosaicism generating a second pathogenic amino acid change in multiple endocrine neoplasia type 2A

[Mutation screening of RET proto-oncogene in Chinese sporadic patients with pheochromocytoma].